Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antibacterianos/efeitos adversos , Dapsona/efeitos adversos , Toxidermias/etiologia , Pneumocystis carinii , Pneumonia por Pneumocystis/tratamento farmacológico , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Adulto , Antibacterianos/imunologia , Reações Cruzadas , Dapsona/imunologia , Toxidermias/imunologia , Substituição de Medicamentos , Feminino , Febre/induzido quimicamente , Febre/imunologia , Humanos , Estrutura Molecular , Trimetoprima/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol/imunologiaAssuntos
Humanos , Feminino , Adulto , Hipersensibilidade a Drogas/diagnóstico , Infecções por HIV/tratamento farmacológico , Dapsona/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Pneumonia por Pneumocystis/tratamento farmacológico , Fatores de Risco , Pneumocystis carinii/patogenicidadeRESUMO
Objetivo La inmunoglobulina específica frente a citomegalovirus ha demostrado su eficacia en la prevención y tratamiento de la infección en el trasplante de órganos sólidos. Distintos estudios indican una eficacia similar respecto a las presentaciones de Ig inespecíficas. El objetivo de este estudio es determinar la titulación de inmunoglobulina anti-citomegalovirus de una de las presentaciones de inmunoglobulinas inespecíficas autorizadas en España. Método Estudio observacional en el que se analizó la titulación de anticuerpos anti-citomegalovirus de distintos lotes de Flebogamma® 5% 5g utilizados en el Hospital Universitari Vall dHebron durante los años 2008 y 2009.ResultadosSe analizaron 27 lotes, que incluyeron 18.944 viales de Flebogamma® 5%. En función del origen, la concentración mediana de inmunoglobulina anti-citomegalovirus fue de 28UPEI/ml y 22UPEI/ml para los viales de origen norteamericano y español, respectivamente (IC 95 % para la diferencia de las medianas de 5 a 6UPEI/ml; p<0 001ConclusionesLa concentración de anticuerpos anti-citomegalovirus de los lotes de inmunoglobulina inespecífica analizados es ligeramente inferior respecto a las especialidades de inmunoglobulinas específicas. Estas diferencias pueden compensarse mediante un ajuste posológico (AU)
Objective Specific immunoglobulin against cytomegalovirus has demonstrated its effectiveness in preventing and treating infections in solid organ transplantation. Several studies indicate that non-specific immunoglobulin is just as effective. This study aims to determine anti-cytomegalovirus immunoglobulin titres from one of the non-specific immunoglobulin presentations authorised in Spain. Method This was an observational study, in which we analysed the anti-cytomegalovirus antibody titres from different batches of Flebogamma® 5% 5g used at the Hospital Universitari Vall d'Hebron during 2008 and 2009.ResultsWe analysed 27 batches, which included 18,944 vials of Flebogamma® 5%. Depending on the origin, the median concentration of anti-cytomegalovirus immunoglobulin was 28PEI-U/ml and 22PEI-U/ml per vial of North American and Spanish origin, respectively (CI 95% for the difference of the medians 5 to 6PEI-U/ml; p<0 001ConclusionsThe anti-cytomegalovirus antibody concentration of the non-specific immunoglobulin batches analysed was slightly lower than in the specific immunoglobulin preparations. These differences can be compensated by adjusting the dosage (AU)
Assuntos
Humanos , Imunoglobulinas/isolamento & purificação , Citomegalovirus/isolamento & purificação , Transplante de Órgãos/efeitos adversos , Biomarcadores/análise , Fatores de RiscoRESUMO
OBJECTIVE: Specific immunoglobulin against cytomegalovirus has demonstrated its effectiveness in preventing and treating infections in solid organ transplantation. Several studies indicate that non-specific immunoglobulin is just as effective. This study aims to determine anti-cytomegalovirus immunoglobulin titres from one of the non-specific immunoglobulin presentations authorised in Spain. METHOD: This was an observational study, in which we analysed the anti-cytomegalovirus antibody titres from different batches of Flebogamma(®) 5% 5g used at the Hospital Universitari Vall d'Hebron during 2008 and 2009. RESULTS: We analysed 27 batches, which included 18,944 vials of Flebogamma(®) 5%. Depending on the origin, the median concentration of anti-cytomegalovirus immunoglobulin was 28PEI-U/ml and 22PEI-U/ml per vial of North American and Spanish origin, respectively (CI 95% for the difference of the medians 5 to 6PEI-U/ml; p<0.001). CONCLUSIONS: The anti-cytomegalovirus antibody concentration of the non-specific immunoglobulin batches analysed was slightly lower than in the specific immunoglobulin preparations. These differences can be compensated by adjusting the dosage.
Assuntos
Infecções por Citomegalovirus/tratamento farmacológico , Citomegalovirus/imunologia , Imunoglobulinas/sangue , Imunoglobulinas/uso terapêutico , Estudos Transversais , Humanos , Estudos RetrospectivosRESUMO
Se describe un caso clínico de intoxicación aguda por carbamazepina. Se realiza una revisión bibliográfica de casos de intoxicación similares descritos anteriormente. Asimismo se enumeran las características farmacocinéticas más destacables de carbamazepina durante un episodio de intoxicación aguda, así como las medidas terapéuticas más adecuadas (AU)
